Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Biogen beats reduced EPS estimates

BGEN reported second quarter operating earnings of $0.39, $0.03 above the Street's consensus and a penny above the high end of BGEN's recently reduced guidance. BGEN's second quarter EPS figure was 26%

Read the full 324 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE